The prices review board was first created 30 years ago to ensure companies do not use monopolies to charge excessive costs for patented medicines.
To conduct these assessments, the quasi-judicial board compares prices with those in a list of other countries. Under the new regime, two of the highest-paying countries, the U.S. and Switzerland, will be removed from the list, and new nations will be added, which could substantially alter the board’s pricing determinations.
The amendments also introduce new economic factors into the review board’s calculations that could dramatically lower the price of new drugs on the Canadian market
Read more here